The Biden administration and drug manufacturers are looking at different ways to keep free access to COVID-19 vaccines; mifepristone remains available without new restrictions while a court battle continues; the goal to reduce HIV in the US by 2030 may fall short, some warn.
US, Drug Makers Look at Ways to Ensure COVID-19 Vaccine Coverage
While Americans with insurance are still expected to be able to get vaccinated for COVID-19 free of charge, it is unclear how the process will work for those without coverage. As the public health emergency for COVID-19, ends, the Biden administration and manufacturers are looking at different ways to ensure free access, according to The Hill. Pfizer and Moderna are expecting the prices of their shots to increase by as much as 4-fold.
Supreme Court Halts Restrictions on Mifepristone
Although the Supreme Court has temporarily preserved access to a medication used in abortion, mifepristone, advocates for reproductive health care are gearing up for a long fight, according to Reuters. The Supreme Court did not rule on the merits of the case, meaning mifepristone could still be restricted or banned at a later stage. Providers welcomed the news but said they are still stockpiling both drugs used in medication abortion—mifepristone and misprostol—just in case access is lost in the future.
Initiative to Reduce HIV Infections May Fall Short of Reaching Goal
The US government has a national initiative to reduce the number of new HIV infections by 75% by 2025 and 90% by 2030 by funding new community-specific strategies to deliver care to marginalized groups, but some question if the target will be reached, according to Kaiser Health News. Launched in 2016, the program practices a new approach to treating and preventing HIV infections that combines telehealth with direct outreach. But people living with HIV, doctors, infectious disease experts, community groups, and some HIV officials say the initiative could miss its main 2030 goal due to complications arising from the pandemic, workforce shortages, anti-LGBTQ+ messaging from some politicians in conservative states, and bureaucratic adversaries.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More